Trial Profile
A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Type 2 Diabetic Patients; EFFECT II
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Omega-3 carboxylic acids (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EFFECT-II
- Sponsors AstraZeneca
- 03 Jul 2018 Primary endpoint (Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)) has been met, according to results published in the Diabetologia.
- 03 Jul 2018 Results (n=84) published in the Diabetologia.
- 14 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.